Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Changes in Abdominal Fat

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Nana Gletsu-Miller, Purdue University
ClinicalTrials.gov Identifier:
NCT00228579
First received: September 27, 2005
Last updated: November 21, 2013
Last verified: November 2013

September 27, 2005
November 21, 2013
June 2003
December 2016   (final data collection date for primary outcome measure)
Visceral adipose tissue volume [ Time Frame: Baseline, 1, 6 and 24 months ] [ Designated as safety issue: No ]
Visceral adipose tissue volume is measured by computed tomography
Not Provided
Complete list of historical versions of study NCT00228579 on ClinicalTrials.gov Archive Site
Insulin sensitivity [ Time Frame: Baseline, 1, 6, 24 months ] [ Designated as safety issue: No ]
Insulin sensitivity is measured by intravenous glucose tolerance test.
Not Provided
Not Provided
Not Provided
 
Assessment of Changes in Abdominal Fat
Assessment of Changes in Abdominal Fat and Metabolic and Tissue Biomarkers During a Bariatric Surgery Weight Loss Intervention Program

In this study, we propose to determine the effect of weight loss on amount of body fat, and on body fat distribution, in severely obese patients. We also want to determine what measurements (waist, hip or thigh circumference) best show the changes in body fat and fat distribution in this group. Most importantly, we want to relate the changes in body measurements to changes in health indicators (blood cholesterol, blood pressure, blood sugars, liver function). With the findings of this study, clinicians should be able to predict an improvement in health based on a change in waist, hip or thigh size. Because this is a pilot study, we will focus on women, who make up the bulk of our clinic population. We will also focus on racial differences between Caucasians and Blacks.

Severe obesity affects 4.7% of the U.S. population. A significant number of these individuals suffer from impaired glucose tolerance and type II diabetes due to insulin resistance (IR). Although it is generally accepted that the accumulation of intraabdominal (IA) fat increases the risk of developing IR, the mechanisms responsible for this phenomenon are not yet understood. In addition, the role of subcutaneous (SC) fat towards the etiology of IR - protective, inert or detrimental - is still under debate. This is because SC adipose tissue releases adipocytokines (IL-6, leptin, TNF-a) that have been demonstrated to impair insulin action. In individuals who are severely obese, hyperinsulinemia may induce an exaggerated production of adipocytokines from IA compared to SC fat stores. Our specific aims are: (1) to determine relative contribution of abdominal SC fat versus IA fat to systemic levels of IL-6, leptin and TNF-a in lean and in severely obese individuals; (2) to determine the effects of systemic adipocytokine concentrations on whole body as well as tissue sensitivity to insulin. Hypothesis: (a) In the context of severe obesity, IA fat produces increased quantities of IL-6, leptin and TNF-a compared to SC fat; (b) In severely obese patients undergoing weight loss, whole body and tissue IR can be predicted by changes in systemic adipocytokines. Methods: Adipose tissue content of IL-6, leptin and TNF-a will be determined by ELISA in biopsies obtained from IA and SC fat stores in lean and severely obese patients. Computer tomography-determined areas of IA and SC fat will be related to changes in systemic adipocytokines at baseline and 6-mo following weight loss therapy. Changes in systemic IL-6, leptin and TNF-a will be assessed from measurements made at baseline and following 6-mo weight loss. For this time period we will also determine changes in whole body (via IVGTT) and tissue sensitivity to insulin (via glucose uptake into muscle and fat). Relationships between systemic adipocytokines and IR will be assessed using uni- and multivariate correlation analysis. These novel studies will determine whether hypersecretion of adipocytokines by IA versus SC adipose tissue induces IR in patients with severe obesity.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Severely obese volunteers who are undergoing bariatric surgery. Subjects will be recruited from patients who are undergoing bariatric surgery procedures at Emory Bariatrics. The costs of surgical procedures are not provided by the research study.

Obesity
Not Provided
Bariatric Surgery
Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2016
December 2016   (final data collection date for primary outcome measure)

Exclusion Criteria:

  1. male [this will be a pilot study limited to females. Gender is known to influence adipose tissue distribution and females represent the majority of the Emory Bariatrics population - 89%],
  2. age less than 18 or greater than 65 y, [aging has been independently associated with insulin resistance]
  3. pregnancy
  4. not eligible for treatment due to medical history (due to cardiac, hepatic or psychiatric problems, or immunocompromise),
  5. tobacco smoker
Female
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00228579
333-2002, DK-067167
No
Nana Gletsu-Miller, Purdue University
Purdue University
National Institutes of Health (NIH)
Principal Investigator: Nana Gletsu Miller, Ph.D. Purdue University
Purdue University
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP